<DOC>
	<DOCNO>NCT02248597</DOCNO>
	<brief_summary>This pilot clinical trial study donor stem cell transplant follow cyclophosphamide treating patient hematological disease . Giving chemotherapy donor stem cell transplant help stop growth cell bone marrow , include normal blood-forming cell ( stem cell ) cancer cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell ( call graft-versus-host disease ) . Giving cyclophosphamide transplant may stop happening .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Followed Cyclophosphamide Treating Patients With Hematological Diseases</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine haploidentical stem cell transplant use post-transplant cyclophosphamide result 60 % good disease free survival ( DFS ) 12 month institution . SECONDARY OBJECTIVES : I . To determine rate acute chronic graft-versus-host disease ( GvHD ) , non-relapse mortality , relapse . OUTLINE : PREPARATIVE REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) daily ( QD ) day -6 -2 . Patients receive myeloablative conditioning receive busulfan IV every 6 hour 16 dos day -7 -4 patient receive reduced intensity condition receive busulfan IV every 6 hour 8 dos day -5 -4 . Patients also receive cyclophosphamide IV QD day -3 -2 TRANSPLANT : Patients undergo stem cell transplant day 0 . GVHD PROPHYLAXIS : Patients receive cyclophosphamide QD day 3 4 , tacrolimus day 5-180 , mycophenolate mofetil day 5-35 . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis hematological malignancy require allogeneic stem cell transplant consistent standard care Hematologic remission disease Lack 8 8 human leukocyte antigen ( HLA ) locimatched related donor HLAmatched unrelated donor Available familial haploidentical ( 4 7 8 HLA locimatched ) donor Significant organ dysfunction &gt; grade 3 Common Terminology Criteria Adverse Events ( CTCAE ) , leave ventricular ejection fraction &lt; 40 % ( evaluated echocardiogram ) &lt; 30 % ( evaluate magnetic resonance image [ MRI ] ) within first 30 day stem cell transplant ( SCT ) Human immunodeficiency virus ( HIV ) positive ( recipient positive hepatitis B [ hepatitis B virus ( HBV ) ] , hepatitis C [ hepatitis C virus ( HCV ) ] human Tcell lymphotropic virus [ HTLV ] I/II exclude participation ) Positive pregnancy test woman childbearing age Estimated probability survive less 3 month Major anticipate illness organ failure incompatible survival form transplant Severe psychiatric illness mental deficiency sufficiently severe make compliance transplant treatment unlikely informed consent impossible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>